Klivira
Request demo

Streamlining Humana Kesimpta Prior Authorization for RMS

Navigating Humana Kesimpta prior authorization for relapsing forms of multiple sclerosis requires a precise understanding of payer-specific workflows and clinical criteria. Klivira streamlines this complex process for healthcare providers.

For revenue cycle directors and prior authorization coordinators, managing high-volume specialty drug PAs like Kesimpta (Ofatumumab) can be resource-intensive. Understanding Humana's specific requirements, from submission channels to appeal pathways, is critical for minimizing delays and denials, ultimately impacting patient access and revenue integrity.

Understanding Kesimpta (Ofatumumab) and its Prior Authorization Context

Kesimpta (ofatumumab) is a high-efficacy anti-CD20 monoclonal antibody indicated for the treatment of relapsing forms of multiple sclerosis (RMS) in adults. As a specialty medication, it frequently requires prior authorization across commercial, Medicare Advantage, and Medicaid managed care plans, including those offered by Humana. Its high cost and specific usage criteria make efficient PA management essential.

Humana's Prior Authorization Channels for Specialty Medications

Humana processes prior authorizations for specialty drugs like Kesimpta through distinct channels. For medications covered under the medical benefit, providers typically utilize the Availity Essentials portal for PA initiation, eligibility verification, and document submission. X12 278 transactions are also supported via clearinghouses. For Kesimpta, which is a self-administered injectable, it's crucial to verify whether it falls under the medical or pharmacy benefit for the specific Humana plan, as pharmacy benefit specialty drugs often route through CenterWell Specialty Pharmacy and ePA platforms like CoverMyMeds or Surescripts.

Humana's Utilization Management Policies for Kesimpta

Humana publishes its medical policies and coverage determination documents on its provider site, outlining the clinical criteria for specialty medications such as Kesimpta. For Medicare Advantage plans, these policies must align with applicable CMS National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs), ensuring that MA plans do not impose criteria more restrictive than Original Medicare. Criteria sources may include Humana-developed guidelines or MCG Health.

Electronic Prior Authorization and Turnaround Times with Humana

Humana actively participates in the HL7 Da Vinci Project ecosystem, indicating a commitment to advancing electronic prior authorization (ePA) capabilities. While medical-benefit ePA adoption varies by procedure category and partner, retail pharmacy benefit PAs often leverage CoverMyMeds and Surescripts. For Medicare Advantage lines, Humana is an impacted payer under CMS-0057-F, mandating standard PA decisions within 7 calendar days and expedited decisions within 72 hours, with phased compliance for API conformance by 2027.

Common Denial Reasons and Appeal Pathways for Kesimpta with Humana

Denials for Kesimpta prior authorizations from Humana commonly stem from reasons such as insufficient documentation of medical necessity, failure to meet step therapy requirements, or non-coverage under NCD/LCD for Medicare Advantage plans. When a denial occurs, Humana outlines clear appeal pathways in its provider manual. For Medicare Advantage members, this includes the CMS-mandated 5-level appeal process, while commercial plans follow distinct reconsideration and appeal procedures, often including peer-to-peer review options.

Frequently asked questions

How do I submit a prior authorization for Kesimpta to Humana?

For medical benefit Kesimpta, submissions are typically made via the Availity Essentials portal or through X12 278 transactions. If Kesimpta is covered under the pharmacy benefit, PA requests may route through CenterWell Specialty Pharmacy or ePA platforms like CoverMyMeds/Surescripts. Always verify the specific benefit and submission channel for the patient's Humana plan.

What clinical criteria does Humana use for Kesimpta prior authorization?

Humana's prior authorization criteria for Kesimpta are detailed in its medical policies and coverage determination documents, accessible on the Humana provider website. For Medicare Advantage plans, these criteria must comply with CMS National and Local Coverage Determinations. Documentation of diagnosis, previous therapies, and clinical rationale for Kesimpta's use are typically required.

What are the expected turnaround times for Kesimpta prior authorization decisions from Humana?

For Humana Medicare Advantage plans, standard prior authorization decisions must be rendered within 7 calendar days, and expedited decisions within 72 hours, as per CMS-0057-F regulations. For commercial plans, Humana publishes its service-level targets on its provider site, which should be verified for current commitments.

What are common reasons for Kesimpta prior authorization denials from Humana?

Common denial reasons include insufficient clinical documentation to establish medical necessity, failure to meet Humana's specific step therapy requirements, or non-adherence to NCD/LCD guidelines for Medicare Advantage beneficiaries. Site-of-care policies may also be a factor for some specialty drugs, though less common for self-administered injectables like Kesimpta.

How can a denied Kesimpta prior authorization from Humana be appealed?

Humana provides clear appeal processes documented in its provider manual and on its provider website. For Medicare Advantage denials, the appeal process follows a 5-level structure mandated by CMS. Commercial plan denials have distinct appeal pathways, often beginning with an internal reconsideration, which may include a peer-to-peer review option.

Related coverage

Other kesimpta prior authorization by payer

Other kesimpta prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo